Madrigal Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Table of Contents
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will participate in the J.P. Morgan Annual Healthcare Conference on January 12, 2026, at 1:30 PM PST. The presentation will be webcast live, offering investors and stakeholders an possibility to hear updates on the company’s progress, particularly regarding its groundbreaking treatment for metabolic dysfunction-associated steatohepatitis (MASH). This announcement underscores Madrigal’s position as a leader in addressing this important unmet medical need.
About Madrigal pharmaceuticals
Madrigal Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for MASH, a severe liver disease affecting a growing number of individuals worldwide. https://www.madrigalpharma.com/
Rezdiffra: A First-in-Class MASH Treatment
Madrigal’s lead medication, Rezdiffra (resmetirom), represents a major advancement in MASH treatment. it is a first-in-class, once-daily oral THR-β agonist specifically designed to address the underlying causes of the disease. Rezdiffra has received approval from both the U.S. Food and drug Governance (FDA) and the European Commission for treating MASH with moderate to advanced fibrosis (F2 to F3). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-nash
Ongoing Clinical Trials
Madrigal is currently conducting a phase 3 outcomes trial to evaluate Rezdiffra’s efficacy in treating compensated MASH cirrhosis (F4c). This trial aims to further demonstrate the potential of Rezdiffra to improve outcomes for patients with the most severe form of MASH. https://www.madrigalpharma.com/pipeline/
Conference Details & Access
Event: J.P. Morgan Annual Healthcare Conference
Date: January 12, 2026
Time: 1:30 PM PST
Webcast access: https://www.madrigalpharma.com/investors/events-and-presentations (A replay will be available after the event.)
Investor & Media Contacts
* Investor Contact: Tina Ventura, IR@madrigalpharma.com
* Media Contact: Christopher Frates, media@madrigalpharma.com
Analysis & Keyword Definition:
* Primary Topic: Madrigal Pharmaceuticals’ participation in the J.P. Morgan Healthcare Conference and updates on its MASH treatment, Rezdiffra.
* Primary Keyword: Madrigal Pharmaceuticals
* Secondary keywords: Rezdiffra, MASH, NASH (Non-alcoholic steatohepatitis), THR-β agonist, J.P. Morgan Healthcare Conference, liver disease, biopharmaceutical, MDGL (stock ticker), clinical trials, FDA approval, European Commission.